首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYTL1 |
| Uniprot No | Q9NRR1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-136aa |
| 氨基酸序列 | MRTPGPLPVL LLLLAGAPAA RPTPPTCYSR MRALSQEITR DFNLLQVSEP SEPCVRYLPR LYLDIHNYCV LDKLRDFVAS PPCWKVAQVD SLKDKARKLY TIMNSFCRRD LVFLLDDCNA LEYPIPVTTV LPDRQR |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYTL1重组蛋白的模拟参考文献示例(实际文献需通过学术数据库核实)：
---
1. **标题**: *Cytokine-like 1 (CYTL1) regulates endothelial cell angiogenesis through VEGF receptor-2 signaling*
**作者**: Smith A, et al.
**摘要**: 研究利用重组CYTL1蛋白发现其通过结合VEGFR2并激活下游PI3K/AKT通路，促进内皮细胞迁移和血管生成，提示其在缺血性疾病中的潜在治疗作用。
2. **标题**: *Recombinant CYTL1 suppresses inflammatory response in macrophages via NF-κB pathway inhibition*
**作者**: Lee B, et al.
**摘要**: 通过原核表达系统制备重组CYTL1蛋白，证实其通过抑制NF-κB信号通路减少巨噬细胞中IL-6和TNF-α的分泌，为抗炎治疗提供新靶点。
3. **标题**: *Expression and functional characterization of human CYTL1 in a mammalian cell system*
**作者**: Garcia R, et al.
**摘要**: 在HEK293细胞中表达并纯化重组CYTL1蛋白，验证其通过趋化因子受体CXCR4介导免疫细胞趋化活性，拓展了对CYTL1免疫调节功能的理解。
4. **标题**: *CYTL1 recombinant protein attenuates cartilage degradation in osteoarthritis models*
**作者**: Kim T, et al.
**摘要**: 重组CYTL1蛋白在骨关节炎模型中显示保护作用，通过抑制MMP-13表达并促进软骨细胞外基质合成，减缓关节退变。
---
建议通过PubMed或Google Scholar搜索关键词“CYTL1 recombinant protein”获取最新研究。
CYTL1 (Cytokine-Like 1), also known as C17orf81. is a small secretory protein initially identified in 2004 through genomic analysis. It belongs to the cytokine family but lacks sequence homology to known cytokines, making its functional classification and mechanistic studies particularly intriguing. The human CYTL1 gene is located on chromosome 22q13.2 and encodes a 15 kDa protein with a conserved N-terminal signal peptide and two cysteine-rich domains, suggesting potential roles in extracellular signaling or protein interactions. Recombinant CYTL1 protein is typically produced using expression systems like *E. coli* or mammalian cells (e.g., HEK293 or CHO), enabling studies on its structure and bioactivity.
Functionally, CYTL1 has been implicated in diverse physiological and pathological processes. Early studies linked it to hematopoietic regulation and vascular development, with evidence showing its ability to inhibit endothelial cell migration and modulate angiogenesis. Recent research highlights its involvement in inflammation, immune responses, and cancer progression. For instance, CYTL1 may regulate macrophage polarization and cytokine secretion, impacting inflammatory diseases. In oncology, it exhibits dual roles: acting as a tumor suppressor in breast and lung cancers by inhibiting proliferation and metastasis, while potentially promoting leukemia progression through unclear mechanisms. These context-dependent effects underscore its complex interaction with microenvironmental factors.
Despite growing interest, CYTL1's receptor and precise signaling pathways remain unidentified, limiting therapeutic exploitation. Recombinant CYTL1 serves as a critical tool to address these gaps, facilitating binding assays, receptor identification, and preclinical validation of its therapeutic potential. Its applications span tissue engineering, cancer immunotherapy, and biomarker development, though further studies are needed to clarify its pleiotropic functions across biological systems.
×
